Sensyne Health PLC's (LON:SENS) Paul Drayson talks to Proactive London's Katie Pilbeam about the highlights from their latest report which includes growing their patient database to over 6.8m records.
He goes on to point out the new commercial agreements signed with the likes of industry heavyweights Bristol Myers Squibb and Alexion.
Added to this Drayson is pleased with the development and launch some key products.
Total revenues for the six months ended October 31, 2020, were £2.3mln; R&D costs were £7.7mln, giving a loss from operations of £9.5mln.